The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Hypoparathyroidism impacts multiple organs and affects an estimated 70,000 to 90,000 people in the U.S. Yorvipath is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

South San Francisco-based Septerna will use most of the IPO proceeds to continue clinical testing of SEP-786 for hypoparathyroidism, an inherited deficiency of parathyroid hormone (PTH).

Hypoparathyroidism is a debilitating endocrine disease caused by a deficiency of the parathyroid hormone (PTH) that results in a range of symptoms, including muscle cramps, fatigue, cognitive ...

Septerna's lead and currently only clinical-stage asset is SEP-786, an orally bioavailable parathyroid hormone (PTH) 1 ...

More severe symptoms include seizures and heart failure. Surgical hypoparathyroidism describes an underactive parathyroid gland and is the most common cause of low calcium levels. Surgical ...

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entera Bio (ENTX – Research Report) today and set a price target of ...

Proof-of-principle data of encaleret, an oral option for post-surgical hypoparathyroidism, were presented at the American Society for Bone Mineral Research meeting demonstrating a concomitant ...